Resources
18 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 12/6/2022 (updated 3/27/2024)
This week, the U.S. Health and Human Services Department, through the Office for Civil Rights (OCR) and the Substance Abuse and Mental Health Services Administration (SAMHSA), announced proposed changes to the Confidentiality of Substance Use Disorder (SUD) Patient Records under 42 CFR part 2 (“Part 2”), which protects patient privacy and records concerning treatment related to substance use challenges from unauthorized disclosures.
Posted 5/24/2022 (updated 3/27/2024)
These contingency management resources include a statement and advisory opinions from the United States Department of Health and Human Services Office of Inspector General. Additionally, the Contingency Management factsheet provides an overview of the approach.
Posted 4/20/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration-funded Opioid Response Network (ORN) initiative has launched the Stand Against Stigma (SAS) Challenge. This is an opportunity for those in the healthcare industry to address and dispel stigma related to individuals with substance use disorders through easy, daily activity.
Posted 3/22/2022 (updated 3/27/2024)
Yesterday, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), is announcing two grant programs totaling $25.6 million that will expand access to medication-assisted treatment for opioid use disorder and prevent the misuse of prescription drugs. By reducing barriers to accessing the most effective, evidenced-based treatments, this funding reflects the priorities of HHS' Overdose Prevention Strategy, as well as its new initiative to strengthen the nation's mental health and crisis care systems.
Posted 3/9/2022 (updated 3/27/2024)
The U.S. Department of Health and Human Services (HHS) together with leading clinicians, researchers, and policy experts led the development of a standard clinical definition for opioid withdrawal in infants to help improve care. It is accompanied with a set of foundational principles that outlines bioethical uses for the definition, distinctly centering around identifying clinical and supportive care needs of mothers and their infants, using an evidence-based, compassionate, and equitable approach.
Posted 3/9/2022 (updated 3/27/2024)
IMPORTANCE Thousands of pregnant people with opioid use disorder (OUD) enter US jails annually,
yet their access to medications for OUD (MOUD) that meet the standard of care (methadone and/or
buprenorphine) is unknown.
OBJECTIVE To assess the availability of MOUD for the treatment of pregnant individuals with OUD
in US jails.
Posted 10/26/2021 (updated 4/3/2024)
Posted 9/22/2021 (updated 4/3/2024)
PCSS's PCSS-Implementation (PCSS-I) initiative is here to support clinicians and their clinical programs by implementing medications for opioid use disorder (MOUD) into your practice.
PCSS-I has clinical and implementation experts as PCSS-I Facilitators available to work with you and your team to develop strategies tailored specifically to support your needs. There is no cost to participate.
Posted 8/19/2021 (updated 4/2/2024)
Addiction Policy Forum, in partnership with Justice Community Opioid Innovation Network (JCOIN) and the National Judicial Task Force to Examine State Courts’ Response to Mental Illness, have released a new online course to help educate judges and court staff on the FDA-approved medications to treat opioid use disorder and their effectiveness for people involved with the criminal justice system.
The course is self-paced and takes approximately 30 minutes to complete. The course aims to prepare participants with the knowledge and information about what substance use disorder treatment involves, the differences between the types of medications used to treat opioid use disorder, and how those medications work.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.